Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0385-0434 in Healthy, Male Japanese Participants
Latest Information Update: 19 Jan 2024
At a glance
- Drugs NNC0385 0434 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 11 Feb 2022 Status changed from recruiting to completed.
- 16 Sep 2021 Status changed from not yet recruiting to recruiting.
- 19 Aug 2021 New trial record